A hallmark of acute and chronic heart failure is the loss of contractile function. 1 Contraction is stimulated by an influx of intracellular Ca 2+ and can be regulated by direct posttranslational modification of the myofilament proteins. 2 The majority of therapies available (eg, β agonists, phosphodiesterase inhibitors) increase intracellular Ca 2+ to strengthen contraction; however, they also have been associated with long-term mortality by increasing diastolic force, by worsening diastolic dysfunction or by promoting cardiac arrhythmias. 3 A promising alternative approach has been the development of inotropic agents that directly increase contraction by enhancing the response of the contractile myofilament proteins to the available Ca 2+ . 4 It has been hoped that this class of drugs would revolutionize the management of heart failure. However, recent clinical trials with Ca 2+ sensitizers such as levosimendan have met with limited success. 3
pairs, forms the core of thiol-based switches that can sense the local redox environment through the unique chemical properties of its thiol side chain. These sensors oscillate between a reduced state and oxidized state, responding to reactive oxygen species or reactive nitrogen species with a continuum of posttranslational modifications. 9 Low fluxes of reactive oxygen species/reactive nitrogen species can function as a signaling mechanism through the formation of reversibly oxidized Cys (eg, disulfide or sulfenic acid-Cys). Higher fluxes can generate irreversibly modified Cys (eg, sulfinic or sulfonic acid-Cys), which may lead to cellular apoptosis and eventually necrosis. 9 Regulatory redox switches have been found in components of excitation-contraction coupling, where they contribute to modulate cardiac contraction, 7 either reversibly, as seen with S-nitrosylation during signaling events, or as more permanent oxidative modifications of the ryanodine receptor, which can lead to dysfunction. 10 The characterization of a similar Cys-based regulation in the myofilaments remains elusive. Skinned cardiac muscle fibers, comprising only the contractile machinery, displayed reduced force generation when treated with oxidizing agents such as H 2 O 2 or Ȯ 2 -, likely in the presence of transition metals. 11, 12 Conversely, cardiac muscles superfused with donors of the thiophylic reactive nitrogen species agent, nitroxyl (HNO), increased force production. 13 This increase in function is notably larger than can be accounted for by the associated rise in Ca 2+ transient, 13, 14 suggesting HNO acts directly on the myofilaments, sensitizing them to Ca 2+ . 15 HNO reacts with the thiol on Cys, forming either a sulfinamide or, in the presence of an additional free thiol, a disulfide bond (Figure 1 ). 16 The effects of HNO on myofilaments have been found to be readily reversible by the reducing agent dithiothreitol (DTT), suggesting that its action involves the formation of intraprotein or interprotein disulfide bonds. 17 Yet, nature and sites of HNO-induced modifications in myofilaments are currently unknown.
Our hypothesis is that HNO induces the formation of intraprotein or interprotein disulfide bonds between critical Cys in the myofilament proteins to enhance contractility. We investigated the effects of two chemically unrelated HNO donors (Angeli salt [AS]) and 1-nitrosocyclohexyl acetate (NCA) 18 on cardiac contraction in intact and skinned muscles and then identified and characterized HNO-modified residues utilizing a new mass spectrometry (MS) site-mapping technique. 
Methods

Steady-State Force-[Ca 2+ ] i Relationships in Skinned Cardiac and Skeletal Muscles
Details for muscle skinning are provided in the Online Supplement. After skinning, the muscles were activated with solutions of varied [Ca 2+ ], whereas diastolic sarcomere length was kept constant. The force-[Ca2 + ] i relationships were generated before and after treatment with NCA (2.5 μmol/L) in the same preparations. After obtaining the force-[Ca2 + ] i relation for the control phase, the muscle was exposed to NCA in relaxing solution for 10 minutes. There was no increase in resting force during the treatment. Afterward, the muscle was activated with activating solutions of varied [Ca 2+ ]containing NCA. These activations in the presence of NCA were repeated once to ensure similar force-[Ca2 + ] i relations were obtained.
Detection of HNO Modifications by Biotin Switch Assay
The HNO-modified thiols were detected using a variation of the standard biotin switch protocol. 19 In brief, 100 μg isolated rat myofibrils/treatment were diluted to 0.5 μg/μL in HEN (250 mmol/L 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid pH 7.4, 1 mmol/L ethylenediaminetetraacetic acid, and 0.1 mmol/L neocuproine), including 0.1% (weight/ volume) sodium dodecyl sulphate [SDS], treated for 10 minutes at 37°C, and removed by acetone precipitation. Treatments included: NCA 2.5 μmol/L; AS 500 μmol/L; and their decomposed, inactive equivalents (reagent at room temperature for >96 hours) in the absence of Ca 2+ . Additional treatments were DTT 5 mmol/L and diethylamine NONOate 125 mmol/L. Remaining free thiols were blocked with 20 mmol/L N-ethylmaleimide. The HNO and/or NO-modified thiols were reduced using 5 mmol/L DTT or 1 mmol/L ascorbate and biotinylated with 0.8 mmol/L N-[6-(Biotinamido)hexyl]-3′-(2′-pyridyldithio) propionamide. Excess N-[6-(Biotinamido)hexyl]-3′-(2′-pyridyldithio) propionamide was removed by acetone precipitation (2 volumes) and resultant pellets were washed with additional acetone. Biotinylated proteins were captured with Ultralink Immobilized Streptavidin, separated by SDS PAGE and silver-stained. For MS studies, 200 μg of starting material was used and after labeling biotinylated proteins were digested overnight with trypsin or chymotrypsin before capture with streptavidin (Online Supplement).
Gel Shift Assay
For 20 minutes at 37°C, 10 μg of rat myofibrils (0.5 μg/μL) were exposed to treatment or control conditions. Samples were diluted to 0.1 μg/μL in lithium dodecyl sulfate sample buffer, treated with 0 or 5 mmol/L DTT, 
Difference In-Gel Electrophoresis Analysis
The NCA/ AS-treated purified tropomyosin (TM) or myofibril samples were labeled using the fluorescent CyDyes 2, 3, and 5 according to the manufacturer's recommended protocol and analyzed by SDS PAGE (Online Supplement).
Statistical Analysis
Student t test and one-way analysis of variance were used for statistical analysis of the data (Systat 10.2). P<0.05 was considered to indicate significant differences between groups. Unless otherwise indicated, pooled data were expressed as mean ± standard error of the mean.
Results
HNO Donors Augment Force Generation in Isolated Cardiac Muscle
In isolated intact cardiac muscle, the HNO donor, NCA, increased force development in a dose-dependent manner from 0.2 to 20 μmol/L with no significant changes in resting force at 0.5 mmol/L [Ca 2+ ] o (Figure 2A and 2B). The NCA (10 μmol/L) augmented force up to 37.7±3.8 mN/mm 2 (P<0.001 vs 8.8±1.0 mN/mm 2 in control muscles). The increase in Ca 2+ transient was not significantly different (0.43±0.11 vs 0.27±0.06 μmol/L control; P=0.23) and diastolic Ca 2+ only increased significantly at high doses. In the presence of NCA, twitch force remained higher at any given external Ca 2+ concentration. However, the amplitude of intracellular Ca 2+ transients was not different from that of control ( Figure 2C ). The force-frequency relationship was also enhanced by NCA without increasing intracellular Ca 2+ concentration ( Figure 2D ).
The disproportionate increase in force compared with changes in Ca 2+ transients may be the result of increased myofilament Ca 2+ responsiveness with NCA. To test this directly, steady-state force-[Ca 2+ ] i relations were obtained by tetanizing the muscles in the presence of ryanodine. Steady-state force-[Ca 2+ ] i relations in control and muscles exposed to NCA (2.5 μmol/L) are shown in Figure 3A . Both maximal Ca 2+ -activated force (F max ) and [Ca 2+ ] i required for 50% of activation (Ca 50 ) increased significantly in muscles exposed to NCA (Table 1 ). Furthermore, the increased Ca 2+ responsiveness persisted after removing membrane-delineated organelles with detergent (skinning), indicating that NCA acts directly on the myofilament proteins ( Figure 3B and Table 1 ). The increases in myofilament Ca 2+ sensitivity caused by HNO were completely abolished by 5 mmol/L DTT ( Figure 3C ), confirming that the effects of HNO are sensitive to reducing equivalents. 17 Although HNO is the primary nitrogenous hydrolysis product of NCA (>50%), other products include acetic acid/sodium acetate and cyclohexanone. 18 These compounds did not produce any measurable effects in the muscles (data not shown). Furthermore, 1-nitrosocyclohexyl pivalate (NCP), a compound of similar chemical structure that does not release HNO, had no effects ( Figure 3D ). 20 Together, these data suggest the positive inotropic effect of NCA is specific to HNO.
HNO Targets Specific Cysteine Residues in the Myofilament Proteins
The nature of the HNO-induced Cys modifications was investigated using a new variation of the biotin switch assay ( Figure  4A ). 19 Isolated rat cardiac myofibrils were used in place of skinned fibers because of ease in preparing sufficient quantities. The Mg-ATPase measurements confirmed the integrity of the myofibrils and NCA treatment resulted in a similar decrease in Ca 50 observed in intact and skinned muscle fibers (Online Figure I) . A change in the maximal myofibril ATPase rate was not anticipated as we have reported previously. 17 For the biotin switch experiments, 5 mmol/L DTT was used to target the same HNO-induced modifications that were reversed in the physiological studies. To compare HNO modification with those induced by NO, 1 mmol/L ascorbate was used to reduce S-nitrosylation groups. 19 The streptavidin capture of intact biotinylated proteins revealed that HNO-modified proteins could be specifically isolated and that they were distinct from those induced by treatment with the NO donor, diethylamine NONOate ( Figure 4B ). The HNO modifications were resistant to reduction with ascorbate, whereas diethylamine NONOate modifications were reversed by both reducing agents.
To map and evaluate the effects of HNO modification on individual Cys, a comparison was performed between the changes induced by NCA with those of the traditional HNO donor, AS. AS co-releases HNO and nitrite whereas NCA decomposes to HNO, acetate, and cyclohexanone. 18, 21 We have previously reported that AS increased F max but did not affect Ca 2+ sensitivity (Ca 50 ) in cardiac muscle. 17 Using the modified biotin switch technique with different donors, a comparative proteomic strategy was devised to parse the effects of the different HNO donors; Cys modifications common to NCA and AS treatments were attributed to the increase in F max , whereas sites unique to NCA were considered candidates for the decrease in Ca 50 . A total of 12 HNO-modified Cys were identified on eight proteins between the two treatments ( Figure  4C and Table 2 ). Of those, four sites (TM Cys190, actin Cys257, myosin heavy chain (MHC) Cys947, and Cys1750) were unique to NCA treatment (Online Table I ).
HNO Induces Dimeric Forms of MHC-Myosin Light Chain and Actin-TM
To investigate the HNO-induced modifications, nonreducing Western blot analysis was used to observe the presence of higher molecular weight species. Higher-molecular-weight forms of actin, TM, MHC, and myosin light chain (MLC1) were found, which were reversed in the presence of 5 mmol/L DTT, indicating HNO induced interprotein disulfide bonds ( Figure 5A ). MHC and MLC1 were found to be modified in a similar manner with both NCA and AS treatment, as indicated by the MS analysis. The 2 higher-molecular-weight species observed were consistent with the formation of an MLC1 homodimer (25 kDa+25 kDa = ≈50 kDa) and an MHC-MLC1 heterodimer (25 kDa+212 kDa = ≈240 kDa). The formation of a The MS analysis of silver-stained gel bands revealed that the actin monomer displays increased gel mobility with NCA. Analysis of other bands revealed that a similar, but less abundant, shift for actin also occurred in AS-treated samples ( Figure  5B and Online Table II ). No molecular-weight shifts were observed for any of the candidate proteins after treatment with the NO donor. The higher-molecular-weight actin and TM bands were examined by SDS-PAGE with better resolution in that region. Comparison of purified TM and isolated myofibrils revealed a higher migration in the NCA-treated myofilament preparations ( Figure 5C, left) . This suggests that in myofilaments, NCA does not induce the formation of a TM homodimer but forms another disulfide-linked interaction. Analysis of the higher forms of actin revealed a difference between the NCA and AS-treated samples. NCA treatment of myofibrils produced a specific band at a slightly lower molecular weight than the bands observed for AS ( Figure 5C, right) . Comparison of the TM and actin NCA bands suggests a linked, co-migrating species. Difference in-gel electrophoresis analysis revealed a distinct myofibril NCA-specific band (Cy3, green) higher than the purified TM homodimer (Cy2, blue) and below a series of AS-specific bands (Cy5, red) ( Figure 5D ). Ca 50 Force - Figure 4 . Detection, capture, and site identification of nitroxyl (HNO) modified proteins. A, Modified biotin switch assay schema outlining thiol blocking, reduction, and biotin labeling steps, as well as capture of intact proteins or digested peptides for mass spectrometry (MS)/MS analysis. 19 B, Silver-stained gel of rat cardiac myofibrils treated with HNO/nitric oxide (NO) donors or control compounds and subjected to the biotin switch assay (n=3). HNO modifications were reduced by 5 mmol/L dithiothreitol (DTT) but were resistant to treatment with 1 mmol/L ascorbate (black arrowheads), whereas NO modifications were reversed with ascorbate (outline arrowhead). C, Summary of subtractive proteomic site mapping study comparing Angeli salt (AS) and 1-nitrosocyclohexyl acetate (NCA) treatments (n=3). Sites specific to NCA treatment were candidates for the Ca 2+ sensitization (Ca 50 ) effect, whereas sites in common were attributed to conferring the maximum force (F max ) increase. See Table 2 for identified sites and Online Table I for MS data. The MS analysis of the molecular weight region identified both actin and TM at the locations that were lost under reducing conditions ( Figure 5E and Online Table II ). These findings, in combination with the site-mapping results, suggest the presence of an NCA-specific heterodimer linked by the formation of a disulfide bridge between TM (Cys190) and actin (Cys257).
Other sites of modification identified in this study were considered as possible candidates for the NCA-specific increase in Ca 2+ sensitivity. The 2 sites identified on MHC (Cys947, Cys1750) with NCA treatment were ruled out. Western blot analysis of MHC revealed no NCA-specific higher-molecular-weight species; only a small shift in common between the two donor treatments, determined to be an interaction with MLC1, was observed. It is possible that an intramolecular disulfide bond was formed between the residues but, considering both modifications were mapped to the linear tail region in areas not known to closely associate, it is unlikely these candidates represent meaningful sites of modification. Additional analysis of the different action of the 2 HNO donors revealed that the co-release of nitrite from AS had no role in inhibiting the formation of the actin-TM heterodimer. Coincubation of NCA and nitrite did not affect heterodimer formation (Online Figure II) .
NCA Increases Ca 2+ Sensitivity but Not Maximum Force Production in Skeletal Muscle Because of the Lack of Dimeric MLC1 Formation
To determine if MLC1 Cys81 is involved in the increased maximum force production, the effect of HNO donors was investigated in skeletal muscle preparations. Skeletal muscle isoforms of myofilament proteins contain all potential target Cys except for MLC1, which lacks the candidate site Cys81, providing a natural mutant sequence ( Figure 6A ). Steady-state force-[Ca 2+ ] i relations of skeletal muscle before and after exposure to NCA (2 μmol/L) are presented in Figure 6B . Ca 50 decreased significantly in the presence of NCA, whereas F max remained unchanged (F max , 33±3.8 vs 31.7±3.7 mN/mm 2 , P=not significant; Ca 50 0.8±0.1 vs 1.07±0.05 μmol/L, P<0.05; Hill, 4.36±0.81 vs 3.47±0.82, P=not significant). The same insensitivity of F max to AS also was observed in skinned skeletal muscles (data not shown). Diagonal gel Western blots revealed an absence of dimeric forms of MLC1 in NCA-treated Table II ). C, Evaluation of the interaction between actin and tropomyosin (TM) with NCA treatment. Purified rabbit skeletal TM (0.03 μg) and isolated rat cardiac myofibrils (1 μg) were treated with NCA or AS and evaluated by one-dimensional 19 nonreducing Western blot probing for TM (left) and actin (right), indicating a co-migrating species reversed by DTT (n=3). D, Fluorescent difference in-gel electrophoresis gel of the same samples were independently labeled: purified TM (Cy2, blue), NCA-treated myofibrils (Cy3, green) and AS-treated myofibrils (Cy5, red) (n=3). E, MS analysis of the same gel region as panel D identified both actin and TM only in the nonreduced lane (n=2) (Online Table II ). This analysis demonstrates NCA-specific actin-TM heterodimer linked by the formation of a disulfide bond. September 28, 2012 skeletal samples but confirmed the presence of a highermolecular-weight form of TM ( Figure 6C and Online Figure  III) . These results indicate that MLC1 Cys81 is a critical residue and redox switch for the HNO induced increase in cardiac force production.
Discussion
The redox switch is emerging as a diverse signaling system for detecting and reacting to changes in the oxidative environment. Disulfide bonds have been the least appreciated candidate for these regulatory modifications. 22 Here, we show that two chemically unrelated HNO donors act directly on specific myofilament proteins to form disulfide bonds between redox switches, which increase Ca 2+ sensitivity and/or force. The HNO treatment resulted in the formation of an actin-TM heterodimer, which correlates with the increase in Ca 2+ sensitivity and dimeric forms of MHC and MLC1, which are associated with increased force generation. These effects are reversed by treatment with reducing agents and distinct from those induced by NO.
HNO Action on the Cardiac Myofilaments
The formation of regulatory disulfide bonds in the myofilaments that enhance contraction is a novel finding. Our data demonstrate that NCA/HNO can specifically enhance myofilament response to Ca 2+ , which correlates with the in vitro formation of an actin-TM heterodimer. In muscle, TM provides a physical barrier, reducing the probability of myosin S1 heads binding to the actin filament during relaxation. 2 When Ca 2+ binds to the troponin complex, TM moves from its inactivated (blocked, B state) state over actin subdomains 1 and 2 to its Ca 2+ -activated (closed, C state) state over actin subdomains 3 and 4. 23 This shift in position increases the probability of myosin binding to the sites on actin, further shifting the position of TM to the fully open (M state) state (Online Figure IV) . [23] [24] [25] Our findings indicate that HNO treatment results in the formation of a disulfide bond between the Cys residues in actin's subdomain 4 (Cys257) and TM (Cys190), 26, 27 given their availability and proximity to each other during activation. [28] [29] [30] The average position and movement of TM over the actin filament is a reflection of equilibrium distribution between the B, C, and M states. 2 In the absence of Ca 2+ , the distribution is approximately 70%, 25%, and 5%, respectively, 31, 32 which changes in response to Ca 2+ or the presence of myosin heads. 33 It is tempting to speculate that the formation of a disulfide bond between Cys190 of TM and Cys257 of actin would tether a subpopulation of TMs in a position over actin's subdomains 3 and 4 similar to the natural C state or M state. This would disturb the local positional distribution of TM and may bias its local equilibrium position toward a state that is more permissive to myosin-binding, effectively priming the myofilaments for Ca 2+ activation. HNO treatments were performed in the absence of Ca 2+ , indicating that myofilament activation is not required for dimer formation. Only low-stoichiometry cross-linking could have a disproportionately large inotropic effect, because the effect on one TM is communicated to neighboring TMs by end-to-end interactions along the actin filament. Such local effects on TM by low-stoichiometry cross-linking do not appear to impinge on its ability to adopt the proper B-state globally, because NCA-treated muscles show normal relaxation kinetics. Increased resting force was observed for intact muscle, but not skinned preparations, and only high HNO concentrations, which correlated with an increase in diastolic calcium, consistent with previous findings. 13, 14 Alterations of TM positional equilibrium by posttranslational modifications have been demonstrated by several recent studies using C-terminus truncated troponin I. [34] [35] [36] An outstanding question in the analysis is a definitive demonstration for the requirement of an actin-TM heterodimer to influence contraction. Although no other potential interactions were identified, conformation of the role of an actin-TM disulfide bond will require additional investigation, including site-directed mutagenesis via an in vivo gene-delivery approach or extraction/reconstitution of the thin filament with gelsolin, fluorescence resonance energy transfer techniques, and three-dimensional cryo-reconstruction of NCA-treated thin filaments. 32, [37] [38] [39] These investigations will be the subject of future studies.
The lack of HNO-dependent increase in skeletal muscle F max is attributable to the absence of the dimeric forms of MLC1 and MHC. Both MHC and MLC1 are essential components of the cross-bridges that form during steady-state activations. F max is dependent on cross-bridge turnover kinetics, the number of cross-bridges, and the force per cross-bridge. 40 Therefore, alterations in the interaction between MHC and MLC1 (specifically, Cys81 of MLC1) likely impacts force production. The regulatory MLC1 is positioned like a collar just below the head region on the MHC (a region called the lever arm 41 ). It has been proposed that the swing of this lever arm produces contraction, which leads to force development. MLC1 plays an essential role in stabilizing the arm. 42 The orientation of these structures brings the identified residue, Cys81, in close proximity with its pair and Cys37 in the enzymatic head region of MHC (Online Figure IV) . We therefore propose that the formation of a covalent interaction in this region, via the HNO-induced disulfide bond, provides additional rigidity of the lever arm, facilitating a stronger swing of the arm, ultimately producing more force. 42 Whether MHC-MLC1 heterodimer or MLC1-MLC1 homodimer is responsible is not clear because neither occurred in skeletal muscle treatments.
The slope of force-[Ca 2+ ] i relation (Hill coefficient) was not altered by NCA treatment, suggesting no change in the cooperative activation of force/ cross-bridges. Cooperative activation occurs through the transmission of Ca 2+ binding to TnC across neighboring functional units, resulting in greater cross-bridge formation. 2, 43, 44 The results indicate that NCA has little effect on Ca 2+ binding to TnC, but instead suggest that it may have a greater influence on the force production of individual cross-bridges rather than the number formed. However, an NCA effect on cooperativity cannot be ruled out because not all aspects of cooperative activation are represented by changes in Hill coefficient. 45 Further investigation will be required to address this possibility.
HNO Donors, Redox Chemistry, and Disulfide Bond Formation in the Heart
The formation of disulfide bonds is not specific to HNO; however, the broader circumstances of HNO-derived disulfide formation appear to be unique among reactive oxygen species and reactive nitrogen species. HNO is capable of forming disulfide bonds and has been shown to enhance in vivo cardiac inotropy; 46, 47 whereas the levels of reactive oxygen species 14 or NO necessary to induce disulfide bonds have been associated with wider cellular dysfunction and, in the case of myocardium, diminished contractility. 48 It is likely the distinct chemistries of these oxidative species are the source of the difference. 21, 49 Reactive oxygen species can lead to rapid and transient disulfide formation via sulfenyl (thiyl) radical or sulfenic acid reactions. Both modifications can then react with nearby available thiols to form disulfides; however, under conditions of persistently high oxidative stress, overoxidation generates sulfinic and sulfonic acids, which prevent this reaction. In contrast, HNO modification results in only one of 2 possible products, a sulfinamide or disulfide. 16 The positive inotropic effects suggest the targeted chemistry of HNO is not predisposed to more harmful and permanent oxidative modifications.
A recent example of the detrimental effects of oxidative stress was presented by Canton et al 50 who reported that left ventricular specimens obtained from explanted failing human hearts displayed greater levels of actin and TM carbonylation that correlated with contractile impairment. Carbonylation is an irreversible posttranslational modification likely formed by the high oxidative stress experienced over the course of heart failure. In addition to carbonylation, they also found that TM participated in a disulfide cross-linked complex. The composition of this complex remains undetermined, although actin was ruled out as a component. These findings highlight that differences in the levels of oxidative stress and the oxidizing agent can determine the type of posttranslational modification formed and dictate the functional or pathological outcome. Our study suggests that HNO induces mildly oxidizing conditions that are manifestly different from those experienced by failing hearts contributing to contractile dysfunction.
One key observation in the current study was that treatment with HNO donors NCA and AS had distinct effects on the myofilaments. Whereas both NCA and AS release HNO, they do so by different mechanisms and rates, yielding different byproducts. AS co-releases HNO and an equal amount of nitrite on protonation, with a half life of 2.1 minutes at 37°C at pH 7.4. 21 Hydrolysis of NCA releases HNO, acetate, and cyclohexanone, with a half life that depends on the reaction conditions (t 1/2 =0.8 minutes in 0.1 N NaOH/MeOH and t 1/2 =>2 hours in pH 7.4 phosphate buffer/MeOH) 18 (Online Figure  V) . The effect of nitrite or a possible reaction between thiol and the NCA compound have been ruled out experimentally (Online Figure II) . The unique physiological effects of AS and NCA are more likely the result of their different release kinetics. The rapid release of HNO by AS is more likely to flood an area, resulting in the simultaneous conversion of opposing thiols to N-hydroxysulfenamides, preventing the formation of a potential disulfide. The much slower HNO release from NCA produces a lower, more constant, concentration of HNO in the system. Low levels of HNO would favor the generation of the N-hydroxysulfenamide intermediate at only one in a pair of proximal thiols. The other thiol would remain unmodified, permitting rapid reaction and disulfide formation before any rearrangement to a sulfinamide (Figure 1 ).
Translational Implications and Conclusions
Because the pharmacological management of acute heart failure has changed little over the past 15 years, our findings also may be of clinical interest. Current available therapies (eg, β agonists, phosphodiesterase inhibitors) increase intracellular [Ca 2+ ] with negative long-term effects. The HNO targets specific redox-switches to enhance the myofilament response to Ca 2+ , without affecting diastolic Ca 2+ levels, and its inotropic action is preserved in failing hearts. 51 Treatment with HNO potentially offers an interesting opportunity to improve both systolic and diastolic functions in heart failure, free from the negative consequences of sustained Ca 2+ manipulation. 4, 13, 14 Clinical trials are ongoing to test this possibility in acutely decompensated heart failure patients. 52 Oxidative modifications in the myocardium primarily have been associated with negative functional consequences, 53 but evidence suggests this may not be uniformly true. Application of the HNO donor, NCA, reproduced and exceeded the performance of previously characterized HNO donors in cardiac tissue. 17 Here, we established that HNO acts directly and reversibly on the myofilament proteins to modify specific cysteine thiols, increasing contractility. Characterization of the covalent interactions between key contractile proteins via the formation of disulfide bonds provides insight into the mechanism of this novel redox-based modulation of cardiac function. These findings provide further support for HNO donors as a potential new class of therapeutic for the management of heart failure.
